Comparison of the Efficacy of Intravenous Labetalol and Intravenous Hydralazine for the Treatment of Hypertension in Patients With Severe Preeclampsia.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 132
- 试验地点
- 1
研究概览
简要总结
Due to limited data regarding preeclampsia from the local population, the debate is still ongoing in the study setting. Hence, the current study was planned to compare the efficacy of labetalol and hydralazine for the treatment of hypertension in patients with severe preeclampsia.
详细描述
As preeclampsia is associated with high perinatal mortality and morbidity, the choice of a better antihypertensive in pregnancy is still debatable. The findings of this study would help evaluate the more efficacious drug between intravenous labetalol and intravenous hydralazine in the management of severe preeclampsia. Based on this empirical evidence, practical recommendations can be developed for routine practice guidelines regarding the optimal drug choice between the two for treating severe preeclampsia and eventually to reduce perinatal mortality and morbidity for both the mother and fetus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant women
- •Both primiparous and multiparous women
- •Aged 20-35 years
- •Gestational age ≥20weeks (assessed on last menstrual period)
- •With severe preeclampsia
排除标准
- •Known allergy to hydralazine or labetalol
- •Deranged liver function tests due to any other cause
- •Women with pre-existing hypertension systolic blood pressure ≥130 mmHg, diastolic blood pressure ≥80 mmHg
- •Patients receiving more than one antihypertensive drug since admission
- •Women with chronic renal failure
研究者
Muhammad Aamir Latif
Research Consultant
RESnTEC, Institute of Research